Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Leases (2020 - 2025)

Historic Current Leases for 10x Genomics (TXG) over the last 6 years, with Q4 2025 value amounting to $11.0 million.

  • 10x Genomics' Current Leases rose 1829.64% to $11.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.0 million, marking a year-over-year increase of 1829.64%. This contributed to the annual value of $11.0 million for FY2025, which is 1829.64% up from last year.
  • As of Q4 2025, 10x Genomics' Current Leases stood at $11.0 million, which was up 1829.64% from $10.5 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Current Leases registered a high of $11.5 million during Q4 2023, and its lowest value of $4.5 million during Q3 2021.
  • In the last 5 years, 10x Genomics' Current Leases had a median value of $9.3 million in 2023 and averaged $8.7 million.
  • Its Current Leases has fluctuated over the past 5 years, first soared by 8801.52% in 2022, then crashed by 1939.94% in 2024.
  • Quarter analysis of 5 years shows 10x Genomics' Current Leases stood at $5.1 million in 2021, then soared by 76.13% to $9.0 million in 2022, then increased by 27.49% to $11.5 million in 2023, then fell by 19.4% to $9.3 million in 2024, then increased by 18.3% to $11.0 million in 2025.
  • Its Current Leases was $11.0 million in Q4 2025, compared to $10.5 million in Q3 2025 and $9.7 million in Q2 2025.